<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568202</url>
  </required_header>
  <id_info>
    <org_study_id>HAEM-4268</org_study_id>
    <secondary_id>U1111-1171-8168</secondary_id>
    <nct_id>NCT02568202</nct_id>
  </id_info>
  <brief_title>Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)</brief_title>
  <official_title>Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in the United States of America (USA). Tha aim of this study is
      bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>An online survey of Prevalence and characteristics of adults with hemophilia B</measure>
    <time_frame>At day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An online survey of Prevalence and characteristics of children with hemophilia B (and their parents)</measure>
    <time_frame>At day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An online survey of Prevalence of psychosocial and other comorbidities in patients with hemophilia B</measure>
    <time_frame>At day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting difficulty with access to treatment (e.g. factor)</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An online survey of Percentage of participants reporting difficulty with access to treatment centers</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting hemophilia interference with employment/education</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting hemophilia interference with physical activities</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting hemophilia interference with relationships</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life: EuroQol</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life:EQ-5D-5L</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life: VAS (Visual Analog Scale)</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life: BPI (Brief Pain Inventory) short form - Pain severity and interference</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life: HAL (Hemophilia Activities List)</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life: HemoCAB (Caregiver Hemophilia Burden Scale</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drivers of psychosocial impact (e.g. hemophilia severity, age, weight, prior treatment history, education)</measure>
    <time_frame>At day 0</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">449</enrollment>
  <condition>Haemostasis</condition>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia B</condition>
  <arm_group>
    <arm_group_label>Survey</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.
There will be no treatment.</description>
    <arm_group_label>Survey</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will investigate adult patients at least 18 years of age with mild-severe
        hemophilia B and caregivers of children (current age below 18 years) with hemophilia B.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged below or equal to 18 years with hemophilia B (any severity, with or
             without inhibitors)

          -  Caregivers of children currently aged below 18 years with hemophilia B (any severity,
             with or without inhibitors)

          -  Subjects must have access to the internet, either at home or at a location convenient
             to them

          -  Provision of informed consent before the start of any survey-related activities

        Exclusion Criteria:

          -  Inability to understand and comply with written instructions in English

          -  Previous completion of the B-HERO-S study with receipt of compensation

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Plainsboro</city>
        <state>New Jersey</state>
        <zip>08536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

